Mammoth Biosciences, a San Francisco, CA-based developer of a CRISPR-based disease detection platform, raised $23m in funding.
The round was led by Mayfield with participation from NFX and 8VC. In conjunction with the funding, Ursheet Parikh, who led Mayfield’s investment, joined Mammoth’s board.
The funds will allow the company to build out its IP portfolio, expand the team, and develop an infrastructure for partners to build on its CRISPR platform, with a focus on pharmaceutical and agricultural partnerships.
Co-founded by Stanford and UC Berkeley PhDs Trevor Martin (CEO), Ashley Tehranchi (CTO), Lucas Harrington, Janice Chen and Jennifer Doudna, Mammoth uses proprietary CRISPR technology licensed exclusively from the University of California to improve disease detection with a point-of-care test that allows fast, simultaneous detection of multiple conditions, in real time, both in the hospital and at home.
The company’s long-term vision is to provide a CRISPR-based platform on which Mammoth and partners can build an infinite number of tests, both within healthcare and also across industries such as agriculture, oil and gas, and forensics.